Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer
NCT05450965
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This phase II clinical trial will study the safety and efficacy of onvansertib to treat patients with small cell lung cancer (SCLC) who have either not responded to or are unable to tolerate chemotherapy. Onvansertib is a drug that inhibits polo-like kinase 1 (PLK-1), an enzyme that is over-expressed in many cancer cells and is involved in cellular repair.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Small-cell Lung Cancer
- Small Cell Lung Carcinoma
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- University of Maryland, Baltimore
- Last updated on ClinicalTrials.gov
- December 17, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Maryland · 1
- University of Maryland Greenebaum Comprehensive Cancer Center · Baltimore, MD
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.